Keywords: Vernalis, Biogen Idec, Vipadenant, V2006/BIIBO14, Parkinson's disease

Vernalis and Biogen discontinue development of vipadenant in favor of an alternative PD candidate

Article | 20 July 2010

Print This

UK drug developer Vernalis says that, along with its partner USA-based Biogen Idec, the companies will continue its novel A2 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in